We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Abbott Laboratories | NYSE:ABT | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.26 | -0.25% | 105.64 | 106.47 | 105.14 | 106.47 | 3,789,738 | 01:00:00 |
From May 2021 to May 2024
By Matt Grossman
Abbott Laboratories has gotten an approval from the U.S. Food and Drug Administration for imaging software that uses artificial intelligence to visualize coronary blood flow and blockages.
The Abbott Park, Ill.-based medical-device maker had already received European approval for the technology, an optical coherence tomography imaging platform using Abbott's Ultreon software.
The technology can help doctors improve treatment plans, Abbott said. "As cardiologists continue to adopt OCT and move away from traditional imaging methods such as angiography, emerging technologies are pivotal to determine the best course of patient care," said Dr. Nick West, Abbott's chief medical officer for its vascular business.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
August 03, 2021 09:27 ET (13:27 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Abbott Laboratories Chart |
1 Month Abbott Laboratories Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
